SALİH DUMAN, ARDA SARIGÜL, BERKER OZKAN, ADALET DEMİR, MURAT KARA, ALPER TOKER
Southern Clinics of Istanbul Eurasia - 2024;35(4):400-404
Objective: Bronchopulmonary carcinoid tumors (BCTs) are a rare type of lung cancer (1 2%). They are divided into two subtypes: typical (TK) and atypical (AK). Prognosis depends on various factors such as tumor type, size, spread, and Ki-67 (cell proliferation marker). This study aimed to identify these prognostic factors to improve treatment and survival rates in BCT patients. The main objective of this research was to retrospectively investigate the factors associated with long-term survival in patients with bronchopulmonary carcinoid tumors. Methods: The data of 56 patients who underwent surgery at our center between February 2008 and March 2021 and were histopathologically diagnosed with bronchopulmonary carcinoid tumor were retrospectively analyzed. Results: Most of the patients were female (60.7%) with a median age of 43. Lobectomy was the most common surgical procedure (60.7%). Prolonged air leak was the most common complication. Typical carcinoids were more common than atypical ones (69.6%30.4%). Mediastinal lymph node metastasis was more common in atypical tumors. The findings of the study showed that tumor stage, lymph node metastasis, and Ki-67 index were prognostic factors associated with long-term prognosis in patients with bronchopulmonary carcinoid tumors. The 5-year survival rate was higher in typical carcinoids than in atypical ones (82.1%64.7%). The recurrence rate was higher in atypical tumors (25%2.4%). Conclusion: These findings highlight the critical role of tumor characteristics in determining long-term outcomes in patients with bronchopulmonary carcinoid tumors. Considering factors such as tumor type, lymph node involvement, stage, and Ki-67 index, more personalized treatment strategies can be developed. Further research involving larger, multicenter patient groups may provide more robust data to improve prognostic models for this patient population and guide treatment decisions.
